Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about ...

Randomized controlled trials provide ‘weak support’ for the idea that ultraprocessed foods are ‘inherently harmful’ simply ...

Qure may seek approval in the UK first while in talks with the FDA about its request for a larger, sham-controlled trial of ...

The risk of cognitive outsourcing is real. But there is reason for optimism, if students are taught good AI habits early and ...

Scaling effective solutions often stalls in state government because funding systems are not designed to reward proof of ...

Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ...

Glucosamine tied to faster progression in people with established neurodegeneration ...

Iovance Biotherapeutics guides for $350M–$370M 2026 revenue with Q2'26 expected to be a record Amtagvi quarter. Read more on ...

Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ ~ Company intends to submit the BLA in third quarter ...

Congenital cytomegalovirus occurs in one out of every 200 babies and is the most common infectious cause of hearing loss and ...

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with ...

Thanks for your interest in UCB and BIMZELX, a key growth driver for UCB. So I'm Head of Patient Impact, as Yvonne mentioned. Essentially, in other companies, this would be called development and ...